Arbutus Biopharma Corp (ABUS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Arbutus Biopharma reported revenue of $14.1M, up 128.2% from $6.2M the year before. Net income was -$33.5M (a -237.9% net margin), or -$0.17 per diluted share. Operating margin was -271.0%. Operating activities generated -$39.6M of cash. At fiscal year end, Arbutus Biopharma held $94.6M in total assets against $18.0M in total liabilities, including $18.0M of cash and equivalents.
Open the full interactive Arbutus Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Arbutus Biopharma Key Stats
| Share Price | $4.11 |
|---|---|
| Market Cap | $811.6M |
| Revenue YoY Growth | +128.2% |
| 52-Week Range | $3.67 – $5.22 |
| Shares Outstanding | 197.5 million (basic, 2026 Q2) |
Arbutus Biopharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.9M | $11.0M | $39.0M | $18.1M | $6.2M | $14.1M |
| Operating Income | -$57.8M | -$73.5M | -$65.5M | -$78.1M | -$76.3M | -$38.2M |
| Pre-Tax Income | -$63.7M | -$76.2M | -$65.0M | -$72.8M | -$69.9M | -$33.5M |
| Income Tax | $0 | $0 | $4.4M | $0 | $0 | $0 |
| Net Income | -$63.7M | -$76.2M | -$69.5M | -$72.8M | -$69.9M | -$33.5M |
| Diluted EPS | -$1.00 | -$0.83 | -$0.46 | -$0.44 | -$0.38 | -$0.17 |
Arbutus Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $529,000 | $1.1M | $179.1M | $1.0M |
| Net Income | -$7.7M | -$3.8M | $169.7M | -$5.1M |
| Diluted EPS | -$0.04 | -$0.02 | $0.87 | -$0.03 |
Arbutus Biopharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $52.3M | $109.3M | $30.8M | $26.3M | $36.3M | $18.0M |
| Current Assets | $127.7M | $160.7M | $151.1M | $132.0M | $127.3M | $94.5M |
| Total Assets | $137.1M | $204.5M | $195.4M | $144.4M | $131.7M | $94.6M |
| Current Liabilities | $9.5M | $11.2M | $32.9M | $22.5M | $15.6M | $6.0M |
| Total Liabilities | $35.1M | $35.0M | $58.6M | $38.4M | $34.3M | $18.0M |
| Shareholders' Equity | $102.0M | $169.4M | $136.9M | $106.0M | $97.4M | $76.6M |
Arbutus Biopharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$51.4M | -$67.5M | -$35.4M | -$85.9M | -$64.8M | -$39.6M |
| Cash From Investing | -$14.9M | -$12.7M | -$74.9M | $50.8M | $22.9M | $15.6M |
| Cash From Financing | $86.7M | $137.2M | $31.8M | $30.6M | $52.0M | $5.7M |
| Free Cash Flow | -$51.7M | -$68.3M | -$35.9M | -$86.9M | -$65.0M | -$39.6M |
Figures from Arbutus Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Arbutus Biopharma financials page for every line item.
Arbutus Biopharma Company Profile
| Ticker | ABUS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Warminster, Pennsylvania |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001447028 |
Frequently Asked Questions
What was Arbutus Biopharma's revenue in fiscal 2025?
Arbutus Biopharma (ABUS) reported revenue of $14.1M for fiscal 2025.
What is Arbutus Biopharma's annual revenue history?
Arbutus Biopharma's annual revenue by fiscal year: 2020: $6.9M; 2021: $11.0M; 2022: $39.0M; 2023: $18.1M; 2024: $6.2M; 2025: $14.1M.
What was Arbutus Biopharma's net income in fiscal 2025?
Arbutus Biopharma reported net income of -$33.5M for fiscal 2025.
What was Arbutus Biopharma's earnings per share (EPS) in fiscal 2025?
Arbutus Biopharma's diluted EPS was -$0.17 for fiscal 2025 (adjusted for any later stock splits).
What was Arbutus Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Arbutus Biopharma reported revenue of $1.0M.
How many shares of Arbutus Biopharma are outstanding?
Arbutus Biopharma reported a weighted average of 197.5 million basic shares outstanding in 2026 Q2.
What is Arbutus Biopharma's market cap?
Based on its latest closing price, Arbutus Biopharma (ABUS) has a market capitalization of about $811.6M.
When does Arbutus Biopharma's fiscal year end?
Arbutus Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Arbutus Biopharma headquartered?
Arbutus Biopharma lists its business address in Warminster, Pennsylvania in its SEC filings.